GlassScriptPhysician profile
Bilal R Khan
NPI 1063670222
$3,742.07
in general payments reported to CMS, 2019-2025
28 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $499 · 2021: $657 · 2022: $806 · 2023: $424 · 2024: $203 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,003.02 | 2019-2025 | Lifevest |
| Philips North America LLC | $427.14 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $402.08 | 2019-2024 | |
| Abbott Laboratories | $327.20 | 2022 | |
| Boston Scientific Corporation | $321.04 | 2020-2023 | Ekosonic |
| Janssen Pharmaceuticals, INC | $172.46 | 2019-2023 | Xarelto |
| Shockwave Medical, INC | $126.77 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.57 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $123.67 | 2020-2023 | Farxiga |
| Medtronic Vascular, INC. | $115.67 | 2019 | |
| Esperion Therapeutics, INC. | $96.92 | 2020 | |
| Amarin Pharma, INC. | $70.07 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $55.81 | 2023-2024 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $42.63 | 2019 | |
| Amgen INC. | $40.99 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $39.71 | 2022-2025 | Opsumit, Uptravi |
| Pfizer INC. | $35.29 | 2023-2025 | |
| Edwards Lifesciences Corporation | $28.50 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Chiesi USA, INC. | $26.26 | 2024 | Kengreal |
| Mallinckrodt Enterprises LLC | $26.02 | 2019 | |
| Stryker Corporation | $25.92 | 2025 | Artix Mt |
| Sanofi-Aventis U.S. LLC | $18.09 | 2019 | |
| Cardinal Health 200 LLC | $17.79 | 2019 | |
| Cook Medical LLC | $17.22 | 2020 | |
| Medtronic, INC. | $16.53 | 2024 | Linq II |
| Sunovion Pharmaceuticals INC. | $14.63 | 2019 | |
| Baxter Healthcare | $14.07 | 2022 | |
| Osprey Medical INC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.